Skip to main content

Availability of GLP-1 Medications

Dear Yale Health Members,

Supply challenges have contributed to a global shortage of of GLP-1 medications, including drugs such as Ozempic, Wegovy, Trulicity, and Saxenda. 

In August, Yale Health created a plan to ensure these medications would be available for patients already using them. A 30-day supply limit was placed on existing prescriptions and new starts for these medications for chronic weight management were halted.

Our Pharmacy and Therapeutics Committee reconvened in late November to review the plan and availability of medications. The committee has recommended the resumption of new starts of GLP-1 medications for patients with higher-risk weight-related conditions. The 30-day limit on prescriptions will be maintained. This will reduce the chance of patients starting the medication and not being able to continue, due to shortages.

If you have questions or concerns about these changes, please contact us. Our primary goal is to provide you with the best possible care during this supply challenge.

Thank you for your understanding and cooperation. Our pharmacy team will continue to track the availability of these medications and provide updates.


Jennifer W. McCarthy, MD     
Chief Medical Officer

Bryan Cretella, PharmD, RPh
Director of Pharmacy & Medication Management